摘要
目的观察普拉克索联合低温血液净化治疗维持性血液透析(MHD)患者并发不宁腿综合征(RLS)的疗效。方法选择我院血液净化中心2015年1月-2019年12月收治的MHD并发RLS患者36例,按照治疗方法分为观察组和对照组,每组18例。观察组给予普拉克索联合低温血液透析,对照组给予普拉克索联合常温血液透析;均治疗4周。分别于治疗前、后对2组进行国际不宁腿综合征研究组评分量表(IRLS)、临床总体印象改善量表(CGI-I)、匹兹堡睡眠质量指数量表(PSQI)进行评分比较。观察并比较2组治疗前后血清铁蛋白、血红蛋白、血磷、甲状旁腺激素、尿素清除率、尿素下降率,记录2组不良反应。结果2组治疗后IRLS、PSQI评分均低于治疗前,且观察组低于对照组(P<0.05)。观察组CGI-I评估显效率高于对照组(P<0.05)。2组治疗前后组间及组内铁蛋白、血红蛋白、血磷、甲状旁腺激素、尿素清除指数、尿素下降率比较差异无统计学意义(P>0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论应用小剂量普拉克索联合低温血液透析治疗尿毒症合并RLS安全有效。
Objective To observe the therapeutic effect of Pramipexole combined with low temperature hemodialysis on restless leg syndrome(RLS),one of the chronic complications of patients undergoing maintenance hemodialysis(MHD).Methods Thirty-six patients with MHD complicated by RLS in Blood Purification Center of our hospital were selected and divided into observation group(n=18)and control group(n=18)according to different treatment methods.The observation group was given oral Pramipexole combined with low temperature hemodialysis,while the control group was given oral Pramipexole combined with normal temperature hemodialysis.Before treatment and at 4 weeks after treatment,International Restless Legs Syndrome Study Group(IRLSSGRS),CGI-I and PSQI scores were compared between the two groups.Serum ferritin,hemoglobin,blood phosphorus,parathyroid hormone,urea clearance rate and urea reduction rate before and after treatment were observed and compared,and adverse reactions were recorded.Results After treatment,the IRLS score and PSQI score of the two groups were lower than those before treatment,and the scores were lower in the observation group than in the control group(P<0.05).The CGI-I efficiency of the observation group was higher than that of the control group,while the PSQI score of the observation group was lower than that of the control group(P<0.05).There was no significant difference in ferritin,hemoglobin,blood phosphorus,parathyroid hormone,urea clearance index and urea decline rate between the two groups before and after treatment(P>0.05).No significant difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Low-dose Pramipexole combined with low temperature hemodialysis is safe and effective in the treatment of patients with MHD and RLS.
作者
鲁华
郭更新
刘爱翔
霍鹏飞
刘倩
刘静
王晶
董林艳
王明铭
张玉静
LU Hua;GUO Geng-xin;LIU Ai-xiang;HUO Peng-fei;LIU Qian;LIU Jing;WANG Jing;DONG Lin-yan;WANG Ming-ming;ZHANG Yu-jing(Nephrology Department,Xingtai People's Hospital Affiliated to Hebei Medical University,Xingtai,Hebei 054000,China)
出处
《解放军医药杂志》
CAS
2020年第11期75-79,共5页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
邢台市科技支撑计划项目(2015zz027-13)。